Drug class
Fumaric acid ester; immunomodulatory disease-modifying therapy for multiple sclerosis
Mechanism of action
The mechanism by which dimethyl fumarate exerts its therapeutic effect in multiple sclerosis is not fully understood. It and its active metabolite monomethyl fumarate activate the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway and may modulate inflammatory and oxidative-stress responses.
General use cases
- Treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, under the applicable product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
